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In this issue of Intensive Care Medicine, Dr. Paul Marik presents his personal critical viewpoint on the use of 
tight glycemic control (TGC) in the intensive care unit (ICU) [1]. He recommends to abandon glycemic control 
all together for critically ill patients, based upon a risk of harm that, in his interpretation, would outweigh any 
possible benefit.  At first sight, dr. Marik’s arguments appear reasonable. However, in our opinion, his 
argumentation was built on a biased/incomplete analysis of the evidence. We here present another (in our view 
more balanced) analysis. We argue that dr. Marik is inadvertently recommending clinicians to throw out the baby 
with the bathwater. 
 
Dr. Marik starts his case with an evolutionary perspective, stating that humans and animals alike reveal 
hyperglycemia when exposed to stress, and thus that this must be beneficial.  We do not agree. Fasted young and 
lean human patients, as well as laboratory mice, in the absence of forced artificial nutrition and hyperglycemic 
drugs such as steroids, indeed mount a metabolic response to stress meant to maintain glucose availability for 
organ systems such as the brain, but this does not - or only very briefly - result in pronounced hyperglycemia. 
Since such a metabolic response to stress is selected by evolution to deal with the inevitable fasting that goes along 
with severe illness or trauma in prehistorical times, an adaptive/beneficial nature is likely. However, the patients 
that we treat in our ICUs worldwide anno 2016 are all but young, lean and without drugs. Our patients are 
supported with interventions and drugs to postpone death that would follow in the pre-ICU era. Dr. Marik 
recommends blood glucose targets up to 220-260 mg/dl as “optimal” for ICU patients, with even higher ranges 
for patients suffering from diabetes. However, there are no RCTs to support this recommendation. In fact, all 
association studies reported a J-shaped curve, with the lowest risk of death present for a blood glucose level within 
or close to the normal fasting range for the age group (80-110 mg/dl for adults, 60-100 mg/dl for children, 50-80 
mg/dl for infants), with increasing risk on the hyperglycemic side and a sharper increasing risk on the 
hypoglycemic end of the spectrum [2]. Of course, associations are no proof of causality, as this requires RCTs.  
The 3 pioneer RCTs on TGC performed in Leuven, showed that targeting age-adjusted normoglycemia (in the 
association studies the lowest risk of death) with insulin improved outcome as compared with tolerating 
hyperglycemia up to the renal threshold (215 mg/dl, above which osmotic diuresis occurs) [3-5]. These benefits 
comprised less morbidity in all three studies and less mortality in the adult surgical ICU population and in critically 
ill infants/children. Thereafter, several large implementation studies and a few small RCTs confirmed better 
outcomes with prevention of severe hyperglycemia [2].  As dr. Marik rightly recalls, after these studies, the concept 
of TGC was (too) rapidly and broadly implemented worldwide which changed the standard of care. Most ICUs 
implemented some sort of glycemic control to prevent excessive hyperglycemia.  This response of the clinical 
community, unfortunately, complicated the design of the later “repeat” multicenter trials that are needed for 
generalisability.  As a result of the changed standard of care, the “control group” was no longer allowed to mount 
that severe hyperglycemic stress response up to the renal threshold (215 mg/dl) as was done in the Leuven RCTs.  
Instead, the control group was treated with insulin to keep blood glucose somewhere between 140-180 mg/dl.  
TGC (mostly targeting 80-110 mg/dl), as compared with that intermediate target range in these studies, either did 
not alter clinical outcomes or, in the largest NICE-SUGAR trial, caused harm [6]. This harm was subsequently 
attributed to the 13-fold increase in hypoglycemia. This contrasted sharply with the outcomes of the Leuven RCTs. 
A careful and critical comparative analysis is needed to provide a scientifically sound explanation.  
 
3  
Dr Marik claims that the beneficial effects of TGC observed in the Leuven RCTs are simply explained by the 
administration of a ‘toxic’ dose of IV glucose as part of the early parenteral nutrition standard of care at that time.  
His claim was based on the results of the multicenter EPaNIC RCT that compared the impact of withholding any 
parenteral nutrition until day 8 in ICU with early initiation of parenteral feeding [7]. The early parenteral nutrition 
comprised intravenous glucose only until the morning of day 3 in ICU, followed by an up-to-target all-in-one 
parenteral nutrition thereafter to supplement any insufficient enteral feeding.  The EPaNIC trial showed that early 
parenteral nutrition caused more infections and organ failure and slowed down recovery. Although this harmful 
effect of early parenteral nutrition could theoretically be due to the glucose load, a post-hoc analysis of the EPaNIC 
trial clearly showed that the higher load of amino-acids, rather than glucose, statistically explained the harm [8]. 
This finding was confirmed by a randomized animal study comparing doses of the various parenteral substrates 
[9].  There is ample evidence from experimental studies that (a) IV glucose does not cause harm as long as glycemia 
is kept normal with insulin [10-12] and (b) that the benefits of TGC are brought about by avoiding toxicity from 
hyperglycemia to cells that do not need insulin for glucose uptake [10, 13-15]. Such cells comprise neurons, 
endothelial cells, hepatocytes, immune cell, renal tubular cells (figure 1). We agree with dr. Marik that early 
parenteral nutrition increases the severity of hyperglycemia. It is thus possible that without early parenteral 
nutrition, benefit from TGC could be less.   
 
But there are other differences to consider, besides the glycemic targets and feeding regimens, that may have 
contributed to the different outcomes of the Leuven RCTs and subsequent trials as NICE-SUGAR [2].  
First, the accuracy of glucose measurement tools should be considered [2]. In order to target a narrow glycemic 
range, an accurate measurement of glycemia is essential.  Without a tool that has an error range several fold smaller 
than the target range, reaching that target is virtually impossible and the risk of dangerous (undetected and 
prolonged) hypoglycemia and glycemic variability inflates dramatically. In the 3 Leuven RCTs, glycemia was 
measured with an accurate blood gas analyzer on arterial blood [3-5]. In many other studies, including NICE-
SUGAR, a variety of inaccurate hand-held glucometers were used, often on capillary blood samples, the latter also 
yielding unreliable measurements in particular during shock.  
A second factor that increases glycemic variability and hypoglycemia is the use of insulin boluses or inaccurate 
infusion pumps. In the Leuven RCTs, in contrast to other studies, insulin was only administered continuously (no 
boluses) with use of accurate syringe pumps connected closely to the patient, through a dedicated lumen of a 
central venous line [3-5].  
A third issue is the level of experience of the nursing team. In the Leuven RCTs, the insulin dose was adjusted 
according to a guideline that allowed intuitive decision-making rather than a simple and unvalidated if-then 
approach in NICE-SUGAR. High level of expertise in the Leuven RCTs explained that 70% of patients were 
strictly within target range (based on average morning glycemia), compared to <50% in NICE-SUGAR (based on 
all measurements) [2].  The Leuven team has subsequently developed a reliable and validated computer algorithm 
[16] that allowed to safely export the concept of TGC to other centers (unpublished). 
Fourth, in the Leuven RCTs, TGC in ICU was stopped when the patient was able to resume oral feeding. In 
some other RCTs, TGC was continued with oral feeds, with intuitively more hypoglycemia and glucose variability.  
Fifth, the way hypoglycemia was corrected may have determined eventual harm. In the Leuven RCTs, any 
rebound hyperglycemia was avoided by an immediate but gentle correction of hypoglycemia.  Hyperglycemia 
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rebound after hypoglycemia, rather than hypoglycemia per se, brings about neuronal damage [17].  A four-year 
follow-up study of the Leuven pediatric RCT showed that TGC improved neurocognitive development, despite 
hypoglycemia [18]. 
 
It is clear that insights in blood glucose management have expanded over the past 15 years. The pioneer RCTs 
showed benefit from preventing severe hyperglycemia but safe and effective implementation requires experience 
and accurate tools. Hypoglycemia and glycemic fluctuations should be avoided, achievable with a validated 
glucose control computer algorithm. However, the optimal blood glucose targets and the interaction with feeding 
strategies remain unclear. Open questions should be the objective of well-designed, adequately powered RCTs. 
They cannot be answered by opinion papers. While awaiting these new RCTs, common sense supports avoiding 
excessive hyperglycemia with targets adjusted to the logistic context per center. It is our opinion that there is 
currently no need to throw out the baby with the bathwater! 
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Figure legend 
 
Fig. 1 Pathological effects of severe hyperglycemia during critical illness. 
Severe hyperglycemia has been shown to induce mitochondrial damage1-3, endothelial dysfunction4,5, increased 
tissular inducible NO synthase (iNOS) expression4,6, altered lipid metabolism7 and systemic inflammation5,8-10 in 
critically ill patients and/or animal models, which in turn lead to an increased risk of muscle weakness11-12, acute 
kidney injury (AKI)3,5,13, liver dysfunction2,5,14, infections15,16 and impaired neurocognitive development17. This 
results in an increased short-term mortality risk15,16 as well as an increased risk of long-term neurocognitive 
impairment17. 
1 Vanhorebeek et al. Lancet 2005; 2 Vanhorebeek et al. Crit Care Med 2009; 3 Vanhorebeek et al. Kidney Int 
2009; 4 Langouche et al. J Clin Invest 2005; 5 Ellger et al. Diabetes 2006; 6 Ellger et al. Intensive Care Med 2008; 7 
Mesotten et al. J Clin Endocrinol Metab 2004; 8 Vlasselaers et al. Ann Thorac Surg 2010; 9 Weekers et al. 
Endocrinology 2003; 10 Ingels et al. J Clin Immunol 2013; 11 Van den Berghe et al. Neurology 2005; 12 Hermans 
et al. Am J Resp Crit Care Med 2007; 13 Schetz et al. J Am Soc Nephrol 2008; 14 Mesotten et al. J Clin Endocrinol 
Metab 2009, 15 Van den Berghe et al. N Engl J Med 2001; 16 Vlasselaers et al. Lancet 2009; 17 Mesotten et al. 
JAMA 2012 
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